USPTO Patent Application: Predicting Disease State by Analyzing cfDNA Fragments
Summary
The USPTO has published a patent application (US20260080975A1) filed by Foundation Medicine, Inc. The application describes methods for predicting disease states by analyzing cell-free DNA (cfDNA) fragments. This is a routine publication of a patent application.
What changed
This document is a publication of a United States Patent Application (US20260080975A1) filed by Foundation Medicine, Inc. The application details methods and systems for predicting a disease state by analyzing cell-free DNA (cfDNA) fragments. The described methods involve determining counts of methylated loci in cfDNA fragments within a specific size range, calculating a disease score by comparing this count to reference samples, and predicting the disease state based on a predetermined threshold.
As this is a patent application publication, it does not impose new regulatory obligations or compliance deadlines on regulated entities. It represents a disclosure of novel technology in the field of diagnostics and personalized medicine. Compliance officers should note this development for potential future impact on diagnostic test development and regulatory pathways for such technologies.
Archived snapshot
Mar 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND SYSTEMS FOR PREDICTING A DISEASE STATE BASED ON ANALYZING CFDNA FRAGMENTS
Application US20260080975A1 Kind: A1 Mar 19, 2026
Assignee
Foundation Medicine, Inc.
Inventors
Mark R. KENNEDY, Justin NEWBERG
Abstract
Methods for predicting a disease based on analyzing cfDNA fragments are described. The methods may comprise, for example, determining, by one or more processors, a test count of methylated loci for cfDNA fragments within a size range for a test sample obtained from a subject; determining, by the one or more processors, a disease score based on comparing the test count of the methylated loci to a reference count of methylated loci from one or more reference samples; and predicting, by the one or more processors, the disease state for the subject based on a comparison of the disease score to a predetermined disease score threshold.
CPC Classifications
G16B 30/10 A61K 45/06 C12Q 1/6855 C12Q 1/6869 G16H 20/10 G16H 50/20 C12Q 2600/154
Filing Date
2025-08-28
Application No.
19313294
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.